Carpegen is a provider of high quality molecular diagnostics. The company focuses on developing and out-licensing real-time PCR assays/kits and point-of-care diagnostics for the diagnosis of specific infections and the detection of genetic biomarkers. As a quality market leader in dental diagnostics Carpegen provides the diagnostic testing system Carpegen Perio Diagnostics for the detection and quantification of periodontal pathogens in gingival samples. This high-quality test is used since 2003 by European dentists for optimizing periodontal therapy. In point-of-care diagnostics, Carpegen has developed the proprietary Gyronimo platform, a benchmarking point-of-care PCR system, delivering rapid, easy-to-use, highly specific & sensitive and highly cost- & personnel-efficient pathogen and genetic marker diagnostics in a broad range of infectious diseases and industrial applications. In December 2016, Carpegen sold the Gyronimo platform to clinical diagnostic specialist Curetis GmbH. The worldwide rights for dental diagnostics, as well as environmental and food safety testing have been retained and are available for licensing/co-development. Currently, Carpegen is participating in two joint R&D projects relating to the development of antibiotic resistance diagnostics (PathoSept project) and water analytics which are funded by the state of North Rhine-Westphalia and the Federal Ministry for Economic Affairs and Energy, respectively. Carpegen is a company with very high quality standards and with a strong emphasis on a sound scientific basis and a proper validation of its diagnostics.